References
China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. Epub ahead of print. Available from: https://doi.org/10.1056/NEJMoa2002032
Bavishi Ch, Maddox T, Messerli F. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiology. Published online April 3, 2020 Available from: https://doi.org/10.1001/jamacardio.2020.1282
Soro-Paavonen A1, Gordin D, ForsblomC, Rosengard-Barlund M, Waden J, Thorn L, SandholmN, Thomas MC, Groop PH; FinnDiane Study Group.Circulating ECA2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens. 2012;30(2):375-83. Available from: https://doi.org/10.1097/HJH.0b013e32834f04b6
Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364-74. Available from: https://doi.org/10.1007/s11427-020-643-8
Dong Chen, Xiaokun Li, Qifa Song et al. Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID19). medRxiv preprint. Available from: https://doi.org/: https://doi.org/10.1101/2020.02.27.20028530
Batlle D, Wysock iJ, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond). 2020;134(5):543-5. Available from: https://doi.org/10.1042/CS20200163
European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. Published March 13, 2020. Consultada en abril 10, 2020.
American Heart Association. HFSA/ACC/AHA statement addresses concernsre: usingRAAS antagonistsin COVID-19. Consultada abril 10, 2020